USPTO serial 88073859
AB CHECK
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Aug 8, 2023
- Examiner
- AVENT, TEAGUE A
- Law office
- TMO LAW OFFICE 126
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with AB CHECK?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Karen L. Elbing
Karen L. Elbing CLARK+ELBING LLP101 FEDERAL STREET, 15TH FLOORBOSTON, MA 02110UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 042 | Scientific and technological services and research projects for the preparation of peptide and antibody libraries, namely, chemical analysis; scientific and technological services and research projects for the identification and characterisation of binding molecules, namely, in the field of antibody discovery, antibody research and antibody optimization in the nature of working on and evaluation of chemical analyses; scientific and technological services and research projects for the preparation, identification and characterisation of peptides and antibodies, namely, medical research in the field of antibody discovery, antibody research and antibody optimization; scientific and technological services and research projects for the preparation and identification of recombinant antibodies, single-chain antibodies, diabodies, tandabs, flexibodies, triabodies, tetrabodies, bivalent antibodies, multivalent antibodies, whole immunoglobulins, and antibody fragments, in particular Fab and scFv fragments, and of nucleic acid sequences coding for these molecules, namely, in the field of antibody discovery, antibody research and antibody optimization, namely, scientific research in the field of antibodies; scientific and technological services and research projects in relation to antibody discovery, namely, medical research in the field of antibody research and drug design; scientific and technological services and research projects in relation to screening of natural, engineered and immunized libraries, namely, medical research in the field of antibody discovery for scientific research services; scientific and technological services and research projects in relation to screening of antibody libraries, namely, in the field of antibody discovery for scientific research services; scientific and technological services and research projects in relation to phage display, phage panning and yeast display vectors, namely, in the field of antibody discovery in the nature of chemical analysis; scientific and technological services and research projects in relation to next-generation yeast display and antibody selection process, namely, in the field of antibody discovery in the nature of chemical analysis; scientific and technological services and research projects in relation to the upstream enrichment of target-specific candidates and batch cloning into yeast-display vectors in the nature of research and development services in the field of antibodies; scientific and technological services in relation to drug discovery by high throughput screen and antibody delivery for therapeutic application, namely, scientific research in the field of antibody research and drug design; scientific and technological services and research projects in relation to batch-cloning and screening of natural, engineered and immunized libraries, namely, scientific research in the field of antibodies and antibody optimization; scientific and technological services and research projects in relation to batch-cloning and screening of antibody libraries, namely, scientific research in the field of antibodies and antibody optimization; scientific and technological services and research projects in relation to antibody development strategies, namely, scientific research in the field of antibody research and antibody optimization; scientific and technological services and research projects in relation to the optimization, maturation and humanization of antibody drug candidates, namely, in the field of antibody research and drug design; scientific and technological services and research projects in relation to multi-factor antibody optimization, namely, scientific research in the field of antibody research and drug design; scientific and technological services and research projects in relation to the optimization of antibody binding affinity, antibody stability, species cross-reactivity, specificity, developability, producibility, and human properties, namely, scientific research in the field of antibody research and antibody optimization; scientific and technological services and research projects in relation to human and non-human lead antibody technology, namely, scientific research in the field of antibody research and antibody optimization | ACTIVE | Sep 27, 2021 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 8, 2023 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Aug 8, 2023 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jul 6, 2023 | SUNA | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | — |
| Jul 5, 2023 | CNPR | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | — |
| Jun 9, 2023 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jun 8, 2023 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Jun 8, 2023 | EX5G | SOU EXTENSION 5 GRANTED | — |
| May 30, 2023 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| May 24, 2023 | EXT5 | SOU EXTENSION 5 FILED | — |
| May 24, 2023 | IUAF | USE AMENDMENT FILED | — |
| May 24, 2023 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| May 24, 2023 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Nov 1, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Oct 28, 2022 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Oct 28, 2022 | EXT4 | SOU EXTENSION 4 FILED | — |
| Oct 28, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| May 19, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| May 17, 2022 | EX3G | SOU EXTENSION 3 GRANTED | — |
| May 17, 2022 | EXT3 | SOU EXTENSION 3 FILED | — |
| May 17, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Oct 28, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Oct 26, 2021 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Oct 26, 2021 | EXT2 | SOU EXTENSION 2 FILED | — |
| Oct 26, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Apr 22, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Apr 20, 2021 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Apr 20, 2021 | EXT1 | SOU EXTENSION 1 FILED | — |
| Apr 20, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Nov 24, 2020 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Sep 29, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 29, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 9, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 26, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 25, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 25, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 25, 2020 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Apr 19, 2020 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Apr 19, 2020 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Apr 19, 2020 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jan 16, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 15, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 15, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 17, 2019 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 17, 2019 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 17, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 13, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 13, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 13, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 2, 2019 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 2, 2019 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 2, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 28, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 21, 2018 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Aug 18, 2018 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 14, 2018 | NWAP | NEW APPLICATION ENTERED | — |